Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report report published on Wednesday morning. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners dropped their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a report on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

AWH stock opened at $0.82 on Wednesday. Aspira Women’s Health has a 52 week low of $0.74 and a 52 week high of $6.01. The company’s 50-day simple moving average is $1.00 and its 200 day simple moving average is $1.92. The company has a market capitalization of $13.20 million, a PE ratio of -0.57 and a beta of 1.47.

Aspira Women’s Health (NASDAQ:AWH) last announced its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The business had revenue of $2.42 million for the quarter, compared to analyst estimates of $2.60 million. During the same quarter in the previous year, the company earned ($0.28) EPS. On average, analysts forecast that Aspira Women’s Health will post -1.26 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its holdings in Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 179,371 shares of the company’s stock after purchasing an additional 53,997 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.73% of Aspira Women’s Health worth $732,000 as of its most recent SEC filing. 12.19% of the stock is owned by institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.